Posts tagged ‘Cancer Signaling’
March 29th, 2011
Sally Church, PhD will be attending the American Association for Cancer Research (AACR) 2011 annual meeting in Orlando that starts this Saturday.
This meeting offers insight into the next generation of PI3K, Akt and mTOR inhibitors, and which compounds have promise for future clinical development.
This is Sally’s favorite meeting of the year as it gives a relaxed opportunity to meet with leading scientists in preclinical drug development and translational medicine.
There will be over 5000 posters, so we hope Sally goes with comfortable shoes for all the walking! You can read updates from the meeting on Pharma Strategy Blog.
March 6th, 2011
Amgen’s denosumab has been shown to reduce skeletal related events (SRE) but not improve overall survival (OS) in prostate cancer.
Icarus Consultants’ oncology new product development expert, Sally Church Ph.D looks at the role of RANKL signaling (the target of denosumab) and recent research on its role in the spread of cancer.
You can gain more insight on this interesting topic from Sally’s Pharma Strategy Blog post.
March 5th, 2011
Both brainstem gliomas and glioblastomas have poor prognosis, which raises the importance of translational medical research that could lead to new targeted therapies.
Research by Phillips et al, has shown that Akt and Notch signaling are hallmarks of poor prognosis, suggesting that identification of molecular subtypes may be useful in the development of new therapies.
February 10th, 2011
Sally Church, PhD is a professional member of the The New York Academy of Sciences (NYAS). Later today she will be at a meeting organized by the cancer & signaling discussion group.
The event titled “Oxidative Stress in Cancer and Exploitation of Negative Regulators as Therapeutics” seeks to explore the role that reactive oxygen and nitrogen species (RONS) have in cancer and inflammation.
There is an impressive line up of speakers. Meetings such as these provide an occasion to hear about early-stage research, translational medicine and provide a window on where oncology new product development opportunities may arise.
They also provide the chance to network and meet key opinion leaders (KOL). Icarus Consultants undertakes KOL market research, and personal relationships are often key to obtaining access to physicians and researchers with extremely busy schedules.
You can find Sally’s forthcoming conference schedule on the Icarus Consultants web site.